Etodolac (Lodine)

Subscribe to Selected New Research on Etodolac

215 relevant articles (38 outcomes, 71 trials/studies) found for this Drug

Description: A nonsteroidal anti-inflammatory agent with potent analgesic and antiarthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ankylosing SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).

Also Known As:

Lodine; AY-24,236; AY-24236; Etodolac, (+-)-Isomer; Etodolac, (-)-Isomer; Etodolac, (S)-Isomer; Etodolac, Monosodium Salt; Etodolac, Monosodium Salt, (+-) Isomer; Etodolac, Monosodium Salt, (S)-Isomer; Etodolic Acid; Ramodar; Ultradol; AY 24,236; AY 24236; AY24,236; AY24236; Acid, Etodolic; Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Indoles: 69

Indoleacetic Acids: 130

Etodolac: 215

5-hydroxyetodolac

6-hydroxyetodolac glucuronide

etodolac glucuronide

Heterocyclic Acids

Indoleacetic Acids: 130

Etodolac: 215

5-hydroxyetodolac

6-hydroxyetodolac glucuronide

etodolac glucuronide

Experts

1.	Shinoda, Motoo: 2 articles (02/2008 - 05/2004)
2.	Ichikawa, Kazuhito: 2 articles (02/2008 - 05/2004)
3.	Tominaga, Keiichi: 2 articles (02/2008 - 05/2004)
4.	Fujii, Shigehiko: 2 articles (02/2008 - 05/2004)
5.	Ono, Yuko: 2 articles (02/2008 - 05/2004)
6.	Fujimori, Takahiro: 2 articles (02/2008 - 05/2004)
7.	Raje, Noopur: 2 articles (07/2006 - 07/2005)
8.	Munshi, Nikhil C: 2 articles (07/2006 - 07/2005)
9.	Ishitsuka, Kenji: 2 articles (07/2006 - 07/2005)
10.	Kanekal, Sarath: 2 articles (07/2006 - 07/2005)

Related Diseases

1.	Pain (Aches) 01/01/1983 - "At the end of the study, patients treated with etodolac showed significant improvement from baseline values in seven of ten clinical variables, namely, painful joints, swollen joints, articular index, pain intensity, morning stiffness, and investigator's and patient's overall assessments" 01/01/1991 - "In addition, the etodolac-treated patients had significant improvement according to the patients' and physician's global evaluations, pain intensity, number of swollen joints, and grip strength" 05/01/2000 - "It was concluded that gait performances improved because of less hip pain and thus a greater range of motion after etodolac intake." 01/01/1990 - "Data are presented from four representative studies that showed the analgesic activity of etodolac in postsurgical pain models" 06/04/2004 - "Our results suggest that etodolac is useful for treatment of neuropathic pain." Order ALL the reference details at left...
2.	Osteoarthritis 01/01/1989 - "The efficacy of etodolac (600 mg/day) and placebo were compared in a 4-week double-blind, parallel-group study involving 104 patients with osteoarthritis of the knee and 106 with osteoarthritis of the hip" 01/15/1999 - "CLINICAL IMPLICATIONS: Etodolac administration for 8 days improved ground reaction forces in dogs with osteoarthritis of the hip joint" 01/15/1999 - "OBJECTIVE: To assess the efficacy of etodolac in improving hind limb function in dogs with osteoarthritis of the hip joint" 01/15/1999 - "Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs." 01/01/1993 - "Worldwide experience with the conventional formulation of etodolac (300 mg b.i.d.) was reviewed in 12 randomized, double-blind, parallel-group studies in patients with osteoarthritis (OA) of the hip or knee" Order ALL the reference details at left...
3.	Rheumatoid Arthritis 02/01/1997 - "Short and longterm safety and efficacy of etodolac in a wide range of dosages in patients with rheumatoid arthritis (RA) are summarized" 02/01/1997 - "Etodolac Study 326 Rheumatoid Arthritis Investigators Group." 02/01/1997 - "Low dose etodolac in rheumatoid arthritis: a review of early studies." 01/01/1993 - "A meta-analysis was done with the data from two studies that provided the first efficacy and safety results for the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis (RA)" 01/01/1993 - "One study included 174 patients with rheumatoid arthritis (RA): 58 received etodolac SR 400 mg once daily (q.d.), 59 received etodolac SR 600 mg q.d., and 57 received etodolac 200 mg twice daily (b.i.d.)" Order ALL the reference details at left...
4.	Gouty Arthritis 01/01/1990 - "In studies of acute gouty arthritis, significant improvement from baseline were seen for all efficacy parameters evaluated for both the etodolac- and naproxen-treated patients" 01/01/1991 - "A double-blind, parallel group study was carried out in 61 patients suffering from acute gouty arthritis to compare the effectiveness of etodolac and naproxen in the relief of symptoms" 01/01/1990 - "In multiple dose studies of acute gouty arthritis and musculoskeletal conditions, etodolac 200 or 300 mg twice a day (b.i.d.) or 200 mg three times a day (t.i.d.) was compared with naproxen 500 mg b.i.d" 01/01/1990 - "The efficacy of etodolac in such conditions is confirmed by the results from eight controlled clinical studies in patients with gouty arthritis, tendinitis and bursitis, and acute sports injuries" 01/01/1990 - "In summary, etodolac therapy for pain following surgery, in acute gouty arthritis and in acute musculoskeletal conditions resulted in analgesia comparable to that provided by several well-established analgesic or anti-inflammatory agents." Order ALL the reference details at left...
5.	Postoperative Pain 08/01/1999 - "This double-masked, parallel-group, randomized study compared the analgesic efficacy and tolerability of a single investigational 1200-mg dose of extended-release etodolac with those of a single 400-mg dose of extended-release etodolac and twice-daily doses of conventional etodolac 200 and 400 mg and placebo given 8 hours apart in 237 patients with moderate or severe postoperative pain following surgical removal of > or = 2 impacted third molars" 01/01/2004 - "Oral etodolac, a COX-2 inhibitor, reduces postoperative pain immediately after fast-track cardiac surgery." 01/01/1990 - "Etodolac: analgesic effects in musculoskeletal and postoperative pain." 01/01/2004 - "PURPOSE: The present study was designed to evaluate the efficacy of a cyclooxygenase (COX)-2 inhibitor, etodolac, on postoperative pain after fast-track cardiac surgery, and to examine the changes in plasma etodolac concentration after oral administration" 06/01/2006 - "Both etodolac and dexamethasone had a significant effect of reducing postoperative pain in patients who had surgical endodontic procedure compared with placebo (P < or = .001)" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Piroxicam (Feldene)
2.	Naproxen (Naprosyn)
3.	Diclofenac (SR 38)
4.	Etodolac (Lodine)
5.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
6.	Aspirin (Acetylsalicylic Acid)
7.	nabumetone (nabumeton)
8.	Indomethacin (Indometacin)
9.	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
10.	Acetaminophen (Paracetamol)

Related Therapies and Procedures

1.	Oral Surgery (Maxillofacial Surgery)
2.	Thoracotomy
3.	Vasectomy (Vas Occlusion)
4.	Heterologous Transplantation (Xenotransplantation)
5.	Drug Therapy (Chemotherapy)

Best Treatments:
Research Summary Report
on Pain

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 8434 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>